We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

90 hedge funds and large institutions have $492M invested in Stoke Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.4% less ownership

Funds ownership: 55.07% → 52.67% (-2.4%)

7% less funds holding

Funds holding: 97 → 90 (-7)

13% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 30

28% less capital invested

Capital invested by funds: $680M → $492M (-$188M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

55% less call options, than puts

Call options by funds: $336K | Put options by funds: $745K

Holders
90
Holders Change
-7
Holders Change %
-7.22%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
26
Reduced
30
Closed
15
Calls
$336K
Puts
$745K
Net Calls
-$409K
Net Calls Change
-$1.04M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.03M
3
TCM
Tekla Capital Management
Massachusetts
+$2.77M
4
Millennium Management
Millennium Management
New York
+$1.53M
5
HS
HighVista Strategies
Massachusetts
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$22.6M
2
SFM
Sphera Funds Management
Israel
-$7.85M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$3.42M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$3.26M
5
BlackRock
BlackRock
New York
-$2.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$92.7M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$62.4M +$8.96M +321,415 +15%
RG
3
Redmile Group
California
$60.6M -$2.14M -76,600 -3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$47M +$3.03M +108,813 +6%
BlackRock
5
BlackRock
New York
$35.9M -$2.85M -102,321 -7%
CAM
6
Cormorant Asset Management
Massachusetts
$32.5M – – –
GGHC
7
Gilder Gagnon Howe & Co
New York
$28.6M -$3.42M -122,601 -10%
State Street
8
State Street
Massachusetts
$23.3M +$274K +9,835 +1%
Federated Hermes
9
Federated Hermes
Pennsylvania
$18.7M -$3.26M -116,993 -14%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$9.24M +$198K +7,089 +2%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$8.59M -$1.39M -49,841 -13%
OCA
12
Octagon Capital Advisors
New York
$7.55M – – –
AG
13
Artal Group
Luxembourg
$6.36M – – –
Northern Trust
14
Northern Trust
Illinois
$4.76M -$287K -10,310 -5%
Goldman Sachs
15
Goldman Sachs
New York
$4.39M +$1.01M +36,361 +27%
Charles Schwab
16
Charles Schwab
California
$3.71M +$261K +9,375 +7%
Morgan Stanley
17
Morgan Stanley
New York
$3.61M -$1.47M -52,765 -27%
CC
18
Casdin Capital
New York
$3.05M – – –
TCM
19
Tekla Capital Management
Massachusetts
$2.52M +$2.77M +99,263 New
VOYA Investment Management
20
VOYA Investment Management
Georgia
$2.11M -$125K -4,477 -5%
Renaissance Technologies
21
Renaissance Technologies
New York
$2.11M +$41.8K +1,500 +2%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$2.06M +$934K +33,500 +70%
Two Sigma Investments
23
Two Sigma Investments
New York
$2.05M -$707K -25,365 -24%
N
24
Nuveen
North Carolina
$1.56M -$854K -30,621 -33%
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
$1.55M -$105K -3,774 -6%
1
2 3 4 5

STOK Hedge Fund Activity: Q3 2021 in Review

90 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2021, worth a combined $492M — down 28% from $680M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of STOK and 8 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 26 added.

The largest buyer was Fidelity Investments, adding an estimated $8.96M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $22.6M sold.

  • 90 institutional investors held Stoke Therapeutics (STOK) as of Q3 2021, down from 97 in Q2 2021.
  • Funds reported $492M of Stoke Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
  • 8 funds opened new Stoke Therapeutics positions in Q3 2021 and 15 closed out, a net change of -7 holders.
  • The largest Stoke Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $8.96M added.
  • The largest Stoke Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $22.6M sold.

Based on aggregated 13F filings for Q3 2021.